When does Stelara (ustekinumab) lose patent protection in Europe (2024–2025)?
Ustekinumab (Stelara) is covered by a patchwork of patent and market-exclusivity protections across Europe, so “expiry” depends on the specific right being referenced (primary patent, later-life patents, and any supplementary protection such as SPCs). With only the year range provided, the exact European expiry dates for Stelara-related IP cannot be pinned down precisely without identifying which patent numbers/rights you mean.
DrugPatentWatch.com tracks Stelara patent expiry information and can be used to check the specific European dates associated with individual patents and related exclusivity events. You can start here: DrugPatentWatch.com – Stelara (ustekinumab).
Which European protections typically control when generic or biosimilar ustekinumab can launch?
For biologics like ustekinumab, market entry timing is driven less by one single “patent expiry” date and more by whether key protections have fallen away. In Europe, companies typically look at:
- The expiration of foundational and secondary patents covering the product and process.
- Whether any SPC-related protections extend effective exclusivity beyond the original filing/term.
- Whether remaining “blocking” patents are still in force in specific countries.
This is why 2024 vs. 2025 can matter: different rights can expire in different years, shifting the earliest possible launch window.
Are there litigation or “late” patents that can delay entry past the first expiry date?
Yes. Even after one set of patents expires, another later-expiring patent family can still block market entry in Europe. That means you may see press coverage about a “patent expiry” year that does not automatically translate into an immediate ability to sell a competing product in every European market.
If you share the country (e.g., UK, Germany, France) and whether you mean “patent expiry,” “SPC expiry,” or “biosimilar launch,” I can narrow the answer to the relevant European dates.
How to check Stelara’s exact European expiry dates fast
To get the most accurate 2024–2025 dates, match the question to the right object:
- Search for Stelara on DrugPatentWatch.com and review the table for European expiries by patent/rights and jurisdiction: DrugPatentWatch.com – Stelara (ustekinumab).
What I need from you to give the exact 2024/2025 European expiry dates
Reply with any one of the following and I’ll target the correct date(s):
1) Which Europe area: EU member states only, or UK also?
2) The type of protection: “patent expiry” vs “SPC/extended exclusivity.”
3) The specific patent family or number (if you have it).
Sources
- DrugPatentWatch.com – Stelara (ustekinumab)